Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17363138 | 0.69 | GABRP (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL21827206 | 0.66 | USP7 (0.36) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15527495 | 0.65 | TSHR (0.34) | ALDH1A1MAPTCYP1A2POLBCYP2C9 | |
| SCHEMBL28841973 | 0.64 | HCAR2 (0.39) | ALDH1A1CYP1A2POLBCYP2C9CYP2C19 | |
| SCHEMBL15527867 | 0.64 | GABRP (0.33) | ALDH1A1MAPTCYP1A2POLBCYP2C9 | |
| SCHEMBL585271 | 0.62 | EDNRA (0.44) | MAPTSMN1; SMN2GABRA1GABRB2KDM4E | |
| SCHEMBL30019041 | 0.62 | NOS2 (0.44) | — | |
| SCHEMBL16913764 | 0.61 | NOS3 (0.32) | ALDH1A1 | |
| SCHEMBL29229877 | 0.61 | KDM4E (0.72) | ALDH1A1MAPTCYP1A2POLBCYP3A4 | |
| SCHEMBL11800402 | 0.60 | HTT (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551487-B2 | PI3K inhibitor for use in the therapy of b cell lymphoma | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2026-02-17 | — | — | US | disclosed |
| US-12257254-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2025-03-25 | — | — | US | disclosed |
| US-11779586-B2 | Compounds comprising tricyclic heterocyclic compounds | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2023-10-10 | — | — | US | disclosed |
| US-11708378-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2023-07-25 | — | — | US | disclosed |
| US-20230066999-A1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | KARUS THERAPEUTICS LIMITED (GB) | 2023-03-02 | — | — | US | disclosed |
| EP-3337460-B1 | COMPOSITIONS COMPRISING TRICYCLIC HETEROCYCLIC COMPOUNDS | CONVALIFE SHANGHAI CO LTD (CN) | 2023-02-15 | — | — | EP | disclosed |
| EP-3337477-B1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | CONVALIFE SHANGHAI CO LTD (CN) | 2023-02-01 | — | — | EP | disclosed |
| US-20220273667-A1 | PI3K INHIBITOR FOR USE IN THE THERAPY OF B CELL LYMPHOMA | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2022-09-01 | — | — | US | disclosed |
| EP-3993804-A1 | PI3K INHIBITOR FOR USE IN THE THERAPY OF B CELL LYMPHOMA | Karus Therapeutics Ltd (GB) | 2022-05-11 | — | — | EP | disclosed |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | KARUS THERAPEUTICS LIMITED (GB) | 2022-04-05 | — | — | US | disclosed |
| EP-3337484-A1 | COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR | Karus Therapeutics Ltd (GB) | 2018-06-27 | — | — | EP | disclosed |
| US-9981987-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
| EP-3105233-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | KARUS THERAPEUTICS LTD (GB) | 2018-03-28 | — | — | EP | disclosed |
| WO-2017029519-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | KARUS THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017029514-A1 | COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR | KARUS THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017029518-A1 | COMPOSITIONS COMPRISING TRICYCLIC HETEROCYCLIC COMPOUNDS | KARUS THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017029517-A1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | KARUS THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | WO | disclosed |
| EP-3105233-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | Karus Therapeutics Limited (GB) | 2016-12-21 | — | — | EP | disclosed |
| US-20160347771-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2016-12-01 | — | — | US | disclosed |
| WO-2015121657-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | KARUS THERAPEUTICS LTD (GB) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708378-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | PIK3CA, PIK3C2A, PIK3C2B | ALDH1A1 3832/4885MAPT 4821/4885CYP1A2 2055/4885 |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | MCL1, MYC, XIAP | ALDH1A1 3418/4885MAPT 2601/4885CYP1A2 3473/4885 |
| US-20220273667-A1 | PI3K INHIBITOR FOR USE IN THE THERAPY OF B CELL LYMPHOMA | BCL6, PIK3R5, BCL9 | ALDH1A1 3039/4885MAPT 4401/4885CYP1A2 3298/4885 |
| US-12551487-B2 | PI3K inhibitor for use in the therapy of b cell lymphoma | BCL9, BCL6, MALT1 | ALDH1A1 4464/4885MAPT 4080/4885CYP1A2 2936/4885 |
| US-12257254-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | MCL1, MYC, XIAP | ALDH1A1 3418/4885MAPT 2601/4885CYP1A2 3473/4885 |
| US-20160347771-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3CA, PIK3C2A, PIK3C2B | ALDH1A1 3832/4885MAPT 4821/4885CYP1A2 2055/4885 |
| US-11779586-B2 | Compounds comprising tricyclic heterocyclic compounds | GRN, GLA, HTT | ALDH1A1 442/4885MAPT 324/4885CYP1A2 1561/4885 |
| US-20230066999-A1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | MCL1, MYC, XIAP | ALDH1A1 3418/4885MAPT 2601/4885CYP1A2 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.